Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$112.46 USD

112.46
6,131,334

-2.05 (-1.79%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $112.48 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Arpita Dutt headshot

Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data

by Arpita Dutt

The biotech sector reacted favorably to President Donald Trump's pick for the top post in the FDA.

    Zacks Equity Research

    Forget Gilead, Buy These Small-Cap Biotech Stocks Instead

    by Zacks Equity Research

    At this juncture, we advise investors to forget Gilead (GILD), a Zacks Rank #4 (Sell) stock, and invest in some other small cap biotech stocks (market capitalization below $200 million) that carry an impressive Zacks Rank.

      Zacks Equity Research

      Sarepta's DMD Drug Launch Slow; What's in Store for 2017?

      by Zacks Equity Research

      We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016.

        Arpita Dutt headshot

        Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal

        by Arpita Dutt

        Biotech stocks felt the heat once again with President Trump tweeting about competition in the drug industry and lowering drug prices.

          Arpita Dutt headshot

          Is This the Right Time to Invest in Biotech Stocks?

          by Arpita Dutt

          The biotech sector rebounded in 2017 and is on a roll since the beginning of the year -- will the rally continue?

            Zacks Equity Research

            Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

            by Zacks Equity Research

            Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

              Sweta Killa headshot

              Biotech ETF (BBH) Hits New 52-Week High

              by Sweta Killa

              This biotech ETF hit a new 52-week high. Are more gains in store for this ETF?

                Zacks Equity Research

                Sarepta (SRPT) Q4 Loss Widens; Sales of Duchenne Drug Slow

                by Zacks Equity Research

                Sarepta Therapeutics, Inc. (SRPT) reported wider than expected loss in the fourth quarter of 2016.

                  Arpita Dutt headshot

                  Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals

                  by Arpita Dutt

                  Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.

                    Arpita Dutt headshot

                    Pricing to Remain Pharma Headline Risk in 2017

                    by Arpita Dutt

                    Drug pricing is an issue that has been weighing on pharma and biotech stocks for more than a year now.

                      Zacks Equity Research

                      United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss

                      by Zacks Equity Research

                      United Therapeutics Corporation (UTHR) reported adjusted earnings of $2.64 per share for fourth-quarter 2016, which missed the Zacks Consensus Estimate of $3.62 by 27.1%.

                        Arpita Dutt headshot

                        Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising

                        by Arpita Dutt

                        While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.

                          Zacks Equity Research

                          Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead

                          by Zacks Equity Research

                          Zacks Investment Ideas feature highlights: Tesla, Volatility Index and Gilead

                            David Bartosiak headshot

                            Five Major Myths about Options Trading

                            by David Bartosiak

                            These are the five biggest myths about options trading

                              Zacks Equity Research

                              Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)

                              by Zacks Equity Research

                              Gilead Sciences (GILD) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.

                                Arpita Dutt headshot

                                Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data

                                by Arpita Dutt

                                Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.

                                  Zacks Equity Research

                                  Gilead (GILD) Announces Data on Combination Therapy for HIV

                                  by Zacks Equity Research

                                  Gilead Sciences, Inc. (GILD) recently announced positive data from a phase II study on HIV cocktail therapy.

                                    Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                                    by Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                                      Zacks Equity Research

                                      Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More

                                      by Zacks Equity Research

                                      The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.

                                        Arpita Dutt headshot

                                        Forget Gilead, Buy These 5 Biotech Stocks Instead

                                        by Arpita Dutt

                                        With Gilead (GILD) providing a not-so-rosy outlook for 2017 as its HCV franchise continues to face challenges, here's a look at 5 biotech stocks that look better-positioned.

                                          Sweta Killa headshot

                                          Biotech ETFs Powered by Q4 Earnings

                                          by Sweta Killa

                                          Improved earnings are driving the biotech space and ETFs higher over the past 10 days.

                                            Zacks Equity Research

                                            Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints

                                            by Zacks Equity Research

                                            Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.

                                              Arpita Dutt headshot

                                              Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib

                                              by Arpita Dutt

                                              Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.

                                                Tracey Ryniec headshot

                                                Healthcare Stocks: The Buying Opportunity of the Year?

                                                by Tracey Ryniec

                                                Tracey and Kevin discuss whether healthcare stocks are still the ???sure things??? they???ve been the last 10 years.

                                                  Madeleine Johnson headshot

                                                  Gilead Sciences Posts Q4 Earnings Beat, Slumps on Weak Guidance

                                                  by Madeleine Johnson

                                                  Gilead Sciences Inc. (GILD) just released its fourth quarter fiscal 2016 financial results, posting earnings, before non-recurring items, of $2.64 cents per share and revenues of $7.3 billion